Classifications

• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
  • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
  • A23L33/12—Fatty acids or derivatives thereof
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
  • A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
  • A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
  • A23D9/007—Other edible oils or fats, e.g. shortenings or cooking oils characterised by ingredients other than fatty acid triglycerides
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23K—FODDER
  • A23K10/00—Animal feeding-stuffs
  • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
  • A23K10/12—Animal feeding-stuffs obtained by microbiological or biochemical processes by fermentation of natural products, e.g. of vegetable material, animal waste material or biomass
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23K—FODDER
  • A23K50/00—Feeding-stuffs specially adapted for particular animals
  • A23K50/80—Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
  • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
  • A23L33/13—Nucleic acids or derivatives thereof
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
  • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
  • A23L33/17—Amino acids, peptides or proteins
  • A23L33/175—Amino acids
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
  • A23L33/17—Amino acids, peptides or proteins
  • A23L33/18—Peptides; Protein hydrolysates
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
  • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P39/00—General protective or antinoxious agents
  • A61P39/06—Free radical scavengers or antioxidants
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
  • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
  • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
  • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C255/00—Carboxylic acid nitriles
  • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
  • C07C255/30—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same unsaturated acyclic carbon skeleton
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
  • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
  • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
  • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
  • C07C57/03—Monocarboxylic acids
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
  • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
  • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
  • C07H19/16—Purine radicals
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
  • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
  • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
  • C07B2200/05—Isotopically modified compounds, e.g. labelled

Definitions

• the present Invention related to isotopically modified compounds and their use as food supplements.
• ROS reactive oxygen species
• RNS reactive nitrogen species
• the damaged protein loses its catalytic or structural activity, but proteases are unable to disintegrate heavily carbonylised strands, so that the damaged species accumulate and aggregate, clogging up cellular passages. This rust-like process gradually wears down all cellular mechanisms, slowing everything down and ultimately causing cellular death.
• diseases such as Alzheimer's, Parkinson's, dementia, cataract, arthritis, chronic renal failure, acute repiratory syndrome, cystic fibrosis, diabetes, psoriasis and sepsis, to give a few examples, are associated with increased protein carbonylation.
• physiological levels of protein carbonyls are at around 1 nmol/mg protein, whereas pathological levels go to 8 nmol/mg and above.
• the oxidizer has been the subject of many studies aiming at neutralizing or removing it by means of increasing the number of antioxidants (vitamins, glutathione, peptides or enzymes).
• the substrate e.g. amino acid (AA) residues which are converted into carbonyls, has received less attention.
• AA residues except proline vulnerable to carbonylation
• the group includes phenylalanine, valine, tryptophan, threonine, isoleucine, methionine, hlsfidlne, arginine, lysine and leucine (arginine is essential for children of up to 5 years of age).
• Oxidation of both Arg and Lys by ROS yields aminoadipic semialdehyd ⁇ and proceeds through sequential replacement of ⁇ -hydrogens with hydroxyls. Oxidation of Lys, Arg, Tip, Thr, Phe and His is shown in Fig. 1. Side-chains undergo the same transformations if these AAs are part of poJypeptides/proteins. Other essential AAs undergoing ROS- driven oxidation include Leu (to 5-faydroxyleucine), VaI (3 -hydroxy valine) and He (several products).
• Fig. 2 Other types of oxidative damages affecting essential AAs Involve reactive nitrogen species (RNS). Examples are shown in Fig. 2.
• RNS reactive nitrogen species
• Nucleic acids are not normally considered as essential components of the diet, but are also damaged by ROS.
• An example particularly important for the mitochondrial functioning is the formation of 8-oxy-G, as illustrated in Fig. 4. This leads to mutations in the mitochondrial genome, which is not maintained and repaired as efficiently as the nuclear genome, with detrimental consequences to the efficiency of respiratory processes in the cell. Another cause of degradation is radiation.
• the kinetic isotope effect is widely used when elucidating mechanisms and rate- determining stages of chemical and biochemical reactions.
• the present Invention is based on the realisation that isotopic substitution can be used to synthesize a class of compounds that, when ingested, result in the formation of bodily constituents (e.g. proteins, nucleic acids, fats, carbohydrates, etc) that are functionally equivalent to normal bodily constituents but which have a greater resistance to degradative/detrimental processes, e.g. those mediated by ROS and RNS or radiation.
• bodily constituents e.g. proteins, nucleic acids, fats, carbohydrates, etc
• degradative/detrimental processes e.g. those mediated by ROS and RNS or radiation.
• a nutrient composition comprises a nutrient composition comprising an essential nutrient in which at least one exchangeable H atom is 2 H and/or at least one C atom is 33 C.
• Compounds for use in the invention are identical to normal nutrients or constituents of food except that they contain stable isotopes which, when Incorporated into bodily constituents make such bodily constituents more resistant to d ⁇ gradative processes than they would be otherwise. They provide a method for protecting the preferred functionality of natural biomolecules; the method comprises supply of a compound in such a way that it becomes incorporated into biomolecules and in so doing confers properties on the biomolecule that protect against damaging or unwanted chemical changes.
• Compounds for use in the invention may be chemically synthesized and, when Ingested by an organism, are metabolized Ia a way that results in the incorporation of the compound into a functional biomolecule; the Incorporation of the compound resulting in the biomolecule having a higher degree of resistance to damaging molecular changes than would be the case for the equivalent biomolecule that did not comprise the compound.
• Such compounds may act as mimics of naturally occurring precursor elements of biomolecules. They may mimic an essential amino acid.
• the organism is typically a plant, microbe, animal or human.
• a compound for use in the invention is typically not degraded by enzymes of the P450 pathway. It can therefore accumulate in a subject for which it is essential.
• the present invention relates to the fact that essential supplements may undergo irreversible chemical transformations such as oxidation, nitration, etc, leading to the onset of senescence or diseases.
• Essential food components cannot be syntheslsed de novo by an organism, e.g. mammal, primate or human, and therefore need to be supplied with the diet.
• a nucleic acid is essential, although it may be more properly be described as conditionally essential.
• Conditionally essential nutrients need to be supplied with the diet under certain circumstances.
• 10 amino acids are essential, i.e. Phe, VaI, Trp, Thr, He, Met, His, Leu, Lys and Arg (up to the age of five).
• Purine and pyrimidine nucleosides are conditionally essential.
• Essential fatty acids are ⁇ -3 and ⁇ 6, while monounsaturated oleic acid is generally non-essential.
• the proposed undesired effects such as ageing/diseases can be slowed down.
• the compounds consumed should be modified Io slow down the undesired reactions, while still retaining their chemical identity.
• This can be achieved in one embodiment by substituting hydrogen atoms subjected to abstraction during oxidatio ⁇ i/oxidative substitution at the most reactive carbon sites, or the sites known to undergo the ROS/RNS inflicted damage as illustrated on Figs. 1-4, with deuteriums, which due to the isotope effect slow down the rate of reactions.
• Substituting carbons instead of or in addition to H atom substitution may require a greater degree of substitution since one does not add so much to the reaction rate decrease (D is twice the weight of H, and 13 C is less than 10% heavier than 12 C).
• a compound for use in the invention may comprise partial or total isotopic substitution.
• deuterium substitution may be only at the one or two hydrogen atoms that are considered chemically exchangable, e.g. at OH or CH 2 adjacent to a functional group. Total rather than partial 13 C substitution may often be achieved more effectively.
• the (or only the) oxidation-sensitive hydrogens should be substituted with deuteriums, to minimize the risk of other metabolic processes slowing down when fragments of these AAs are used to build up other structures.
• both 1 H and 12 C of a H-C bond can be substituted by 2 H and 13 C.
• isotopes such as unwanted slowing down of biochemical reactions that utilise fragments of AAs protected with isotopes
• preferably only the most sensitive parts of the AAs should be derivatised, for example, ⁇ -atoms of Lys and Arg. Preferred compounds of this type are
• AAs As all vertebrata have lost the ability to synthesise the essential AAs and require the outside supply of essential AAs or fatty acids, non-painful ways of delivering the deuterated/deuterated and 13 C-modified AAs into human food sources are possible.
• one example of process is to create essential AAs-deficient yeast/algae/bacteria/etc, growing them on appropriate isotopically 'protected' media/substrates and then feeding the obtained biomass to fish or livestock. The fish or livestock can then be introduced into the food chain in the normal manner. Another example is by a direct pill/supplement-based delivery.
• Non-essential components of food are the compounds that can be produced by an organism, such as nucleic acid bases. But when these are consumed as food, some of the non-essential components are digested/used as precursors for other compounds, but a certain fraction is utilized directly in metabolic processes, e.g. nucleic acid (NA) bases, incorporated into DNA. Therefore, as an example, some of the NA bases supplied with food may be isotopically protected, as shown in the following, illustrative formulae
• Such species are less vulnerable to oxidation upon incorporation into DNA.
• the oxidation rate of DNA including mitochondrial DNA, can be reduced.
• a composition of the invention can be provided like any food supplement. It typically comprises one or more nutrients in addition to the isotopically labelled essential component. It may comprise plant material, microbial material or animal material.
• the composition may be a normal foodstuff, a tablet or other solid medicament, or an injectable or other liquid.
• composition may comprise unmodified compounds in addition to those that have been labelled.
• the labelled compound is typically present in a larger amount, and certainly greater than that which may be present naturally.
• Compounds for use in the invention may be prepared by procedures that are known or that can be modified as appropriate by one of ordinary skill in the art,
• the deuterat ⁇ d analogue of Ly s. 2,6-diaminohexanoic a.dd- ⁇ ,6-D2 may be synthesized from a precursor nitrile by hydrogenolysis in D 2 according to standard procedures.
• the deuterated analogue of Arg, 2-amino-5-guanidinopentanoic acid-5,5-Z)2, may be synthesized from a corresponding nitrile.
• Omithine-Da obtained by hydrogenolysis in a way similar to that described above for Lys, was dissolved in water and mixed with an equal volume of 0.5M O-methy ⁇ sourea, pH 10.5, adjusted with NaOH. After 4-5 h, 1% TFA was added to stop the reaction. The compound was purified by a RP HPLC (Buffers were A: 0.1% TFAZH 2 O; B: 0.1% TFA/ (80%MeCN / 20% H 2 O)), 0-65 % B over 40 mm. See Kimmel, Methods Enzymol. (1967), 11: 584-589, and Bonetto et al, Anal. Chem. (1997), 69: 13154319.
• Cyano-aminoacids are precursors to amino acids. Synthesis of cyano-aminoacids can be carried out by several routes, starting from a variety of precursors. Alcohols (Davis & Untch, J. Org. Chem. (1981);46: 2985-2987), amines (Mihailovic et al, Tet. Lett. (1965) 461-464), amides (Yamato & Sugasawa, Tet Lett. (1970) 4383-4384) and glycine (Belokon et al, JACS (1985)107: 4252-4259) can all serve as starting materials in such syntheses. Some methods can yield both 13 C and 2 H-substituted compounds, while others are only compatible with deuterat ⁇ on.
• Deuteration can be carried out using deuterium gas (for example, as described in White et at, JACS (1994) 116: 1831-1838) or different deuterides, for example NaBD 4 (Satoh et al, Tet. Let. (1969) 4555-4558): the choice between these methods should be made based on the availability and price of the corresponding deuterium derivatives. Some of the strategies tested are described in detail below.
• the sites to be protected within essential fatty acids for the purpose of the present invention are the methylene groups of the 1,4-diene systems ('bis-allyl' positions). They are the most reactive, and can easily be derivatised using a variety of methods. Bromination of this position followed by reduction with 2 H 2 results in the substitution of one hydrogen at a time. To substitute both, the procedure should be repeated twice. A more attractive method may be a direct one-step substitution in heavy water. An example of such exchange is given below (Example 6) for 8-deuteration of deoxyguanosine.
• the invention is not limited by the synthetic organic chemistry methods described above, as there exists a large arsenal of different methods that can also be used to prepare the above mentioned and other isotopically protected components suitable for use in the present invention.
• other methods suitable for convention of a primary amino group function into a CN function can be employed, such as: a direct oxidation by oxygen catalysed by cuprous chloride-dioxygen-pyridine system (Nicolaou et al, Synthesis (1986) 453-461: Capdevielle et al, Tet. Lett,
• the reaction mixture was stirred under argon at 6O 0 C for 6 h, with monitoring by TLC (chloroform/methanol 2:1, visualization in iodine vapor). Upon completion, the reaction mixture was cooled to RT, diluted with water (100 ml) and extracted with diethyl ether (2 x 50 ml). The organic phase was washed with water (4 x 50 ml) and brine (50 ml), dried (Na 2 SO 4 ), decanted and concentrated in vacuo to yield (2.07 g, 91%) of colorless oil
• the structure of the Boc-nitri ⁇ e was confirmed by MALDI-TOF (Voyager Elite, PerSeptive Biosystems), with HPA as a matrix. Found: 229.115 (MI), 230.114 (MI + H + ), 252.104 (MI + Na + ). No peaks related to the starting material were detected.
• the aqueous fraction was saturated with brine, washed with diethyl ether (2 x 20 mi), and acidified to pH 3.5 with sulphuric acid.
• the product was extracted with ethyl acetate (2 x 20 ml). Combined organic fractions were dried (brine, Na 2 SO 4 ) decanted and evaporated to give 3.46 g (76%) of colorless oil.
• the structure of the Boc-nitrile was confirmed by MALDI-TOF (Voyager Elite, PerSeptive Biosystems), with HPA as a matrix. Found: 228.114 (MI), 229.114 (MI + H + ), 251.103 (MI + Na + ). No peaks related to the starting material were detected.
• the product was redisolved in water-ethanol (3:1; 20 ml) followed by evaporation in vacuo (x 4) and then crystallized from ethylacetate to give 11.55 g (78%) of the deuterated product.
• the structure of deuterated lysine was confirmed by MALDI-TOF (Voyager Elite, PerSeptive Biosystems), with HPA as a matrix. Found: 148.088 (MI), 149.089 (MI + H x ).
• reaction mixture was quenched by acidification (IM HCl) followed by acetone, and purified by ion exchange (Amberlite IR120P (H”), Aldrich).
• IM HCl acidification
• acetone acetone
• ion exchange Amberlite IR120P (H"), Aldrich
• Linolelc acid (7 g, 25 mmol, Aldrlch) was dissolved in 25 ml of carbon tetrachloride dried over P 2 Os.
• N-bromosuccinimide (4,425 g, 25 mrnol, desiccated overnight over P 2 O 5 ) and 0.05 g AIBN were added, and the reaction mixture in a flask with a reversed condenser was stirred with gentle heating till the reaction was initiated as manifested by an intense boiling (if the reflux is too intense the heating should be decreased).
• succinimide stopped accumulating on the surface, the heating was continued for another 15 mill (about 1 h in total).
• 11 , 11 -Di-Linoleic acid (18:2) was synthesized by treating linoleic acid with an eqv of a BuLi-tBuK (Sigma-Aidrich) mix in hexatie followed by quenching with D 2 O. To improve yields this procedure needs to be repeated 3-4 times.
• BuLi-tBuK Sigma-Aidrich
• Deoxyguanosine (268 mg, 1 mmol, Aldrich) was dissolved in 4 ml of D 2 O. 10% Pd/C (27 mg, 10 wt% of the substrate, Aldrich) was added, and the mixture was stirred at 16O 0 C in a sealed tube under B 2 atmosphere for 24 h. After cooling to RT, the reaction mixture was filtered using a membrane filter (Mil ⁇ pore Millex ® -LG). The filtered catalyst was washed with boiling water (150 ml), and the combined aqueous fractions were evaporated in vacuo to give deoxyguanoside-J as a white solid (246 mg, 92 %). The structure of the nucleoside was confirmed by MALDI-TOF (Voyager Elite, PerSeptive Biosyst ⁇ ms), with HPA as a matrix. Found: 268.112 (MI).
• Pd/C catalyst prepared from PdCl 2 as described in Chiriac et al (1999) 42: 377-385, was added to a solution of 8-bromodeoxyguanosine (Sigma) and NaOH in water. The mixture was stirred in D 2 (2 atm) at 30 D C. The catalyst was filtered off and the reaction mixture was neutralized with 2N HCL The procedure provides approx. 85-90% yield of the product.
• Other reducing agents can be employed, such as NaBD4 (see the synthesis of D,D'linoleic acid).
• Examples 10 to 12 illustrate the utility of the invention.
• the influence of heavy carbon ( 13 C) and specifically "protected' building blocks of biopolymers (nucleic acid components (nucleosides), lipids and amino acids) on the life span was tested on a nematode Caenorhabditis elegans.
• Example 10 l 3 € 6 -glucose (99% enrichment; Sigma) was used as a carbon food source for culturing of Escherichia coli; the control was identical except for the !2 € ⁇ rglucose.
• C elegans (N2, wild type) were grown on a standard (peptone, salts and cholesterol) media seeded with Escherichia coli prepared as decribed above.
• the only carbon-containing component apart from E. coli was 12 C -cholesterol (Sigma; a hormone precursor that is essential for C. elegans ⁇ , since the corresponding ' 3 C -derivative was unavailable.
• Nematodes were thus grown on a 'heavy' and 'light' (control) diet in the temperature range of 15-25 0 C, in pools of 50-100 worms each. The animals on both diets developed normally with all major characteristics being very similar.
• the longevity data was analyzed using Prism software package (GraphPad software, USA), according to published procedures (Larsen et al, Genetics 139: 1567 (1995)). It was found that animals on the 'heavy' diet have an increase of a lifespan of around 10% (in a typical experiment, 14 days for 12 C animals versus about 15.5 days for the 13 C -fed worms, for 25 0 C).
• C. elegans (N2, wild type) were cultivated on this medium.
• nematodes were grown on a medium prepared as above but containing standard L-Arg and L-Lys instead of the deuterated analogues, in the temperature range of 15-25°C, in pools of 50-100 worms each.
• the longevity data was analyzed using Prism software, as described in Example 10.
• a 12 C-NGM die! was enriched with 5,5-di-deulero-argIn ⁇ ne and 6,6-di-deu.tero-lysine, l i,l l-di-deuter ⁇ -linoleic acid (18:2), and 8-D-deoxyg ⁇ ian ⁇ sIne.
• C elegans were grown on a standard (peptone, salts and cholesterol) medium seeded with Escherichia coli prepared as described above, to which deuterium- 'reinforced' derivatives (see above) were added, to a total concentration of lg/L of each deuterated compound.
• Nematodes were thus grown on a 'heavy' and 'light' (control- whereby nori-deuterated L-Arginine, L-Lys ⁇ ne, linoleic acid (18:2). and deoxyguanosine were used instead of deuterated analogues in lg/L concentrations) diet in the temperature range of 15-25 0 C, in pools of 50-100 worms each.
• the longevity data was analyzed using Prism software package, as described in Example 10.

Landscapes

• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Polymers & Plastics (AREA)
• Food Science & Technology (AREA)
• Organic Chemistry (AREA)
• Nutrition Science (AREA)
• Mycology (AREA)
• Molecular Biology (AREA)
• Biochemistry (AREA)
• General Health & Medical Sciences (AREA)
• Biotechnology (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Zoology (AREA)
• Animal Husbandry (AREA)
• Epidemiology (AREA)
• Genetics & Genomics (AREA)
• Marine Sciences & Fisheries (AREA)
• Insects & Arthropods (AREA)
• Birds (AREA)
• Botany (AREA)
• Sustainable Development (AREA)
• Biomedical Technology (AREA)
• Microbiology (AREA)
• Physiology (AREA)
• Dermatology (AREA)
• Toxicology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Saccharide Compounds (AREA)

Priority Applications (11)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=36241193

Family Applications (1)

Country Status (8)

Cited By (13)

Families Citing this family (6)

Citations (4)

Family Cites Families (24)

• 2006
  • 2006-03-08 GB GBGB0604647.8A patent/GB0604647D0/en not_active Ceased
• 2007
  • 2007-03-08 US US12/281,957 patent/US8906405B2/en active Active
  • 2007-03-08 CA CA2645038A patent/CA2645038C/en active Active
  • 2007-03-08 JP JP2008557833A patent/JP5844955B2/ja active Active
  • 2007-03-08 DK DK07712990.6T patent/DK1991068T3/en active
  • 2007-03-08 ES ES07712990.6T patent/ES2639395T3/es active Active
  • 2007-03-08 CA CA2931996A patent/CA2931996A1/en not_active Abandoned
  • 2007-03-08 EP EP07712990.6A patent/EP1991068B8/en active Active
  • 2007-03-08 EP EP17174428.7A patent/EP3339315B1/en active Active
  • 2007-03-08 WO PCT/GB2007/050112 patent/WO2007102030A1/en not_active Ceased
• 2014
  • 2014-11-24 US US14/551,450 patent/US9320289B2/en active Active
• 2015
  • 2015-03-09 JP JP2015045737A patent/JP6062470B2/ja active Active
• 2016
  • 2016-03-23 US US15/078,853 patent/US9616042B2/en active Active
• 2017
  • 2017-03-01 US US15/446,922 patent/US10015979B2/en active Active
• 2018
  • 2018-06-22 US US16/016,023 patent/US10918126B2/en active Active

Patent Citations (4)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events